Notice of Results and Investor Presentation

Summary by AI BETAClose X

Vulcan Two Group plc will announce its Half Year Results on Tuesday, 29 September 2026, and will host a live investor presentation at 11am BST on the same day via the Investor Meet Company platform. The company, which is building a regulated UK ePharmacy through a buy-and-build strategy, is open to questions from existing and potential shareholders submitted pre-event or during the live presentation.

Disclaimer*

Vulcan Two Group PLC
24 September 2026
 

 

24 September 2026

Vulcan Two Group plc

(the “Company”, "Group" or "Vulcan Two")

 

Notice of Results and Investor Presentation

 

Vulcan Two Group plc, the Company building a leading regulated UK ePharmacy through buy and build, will announce its Half Year Results on Tuesday 29 September 2026. Following the release of the results, the Company’s management team will be hosting a live presentation at 11am (BST) on 29 September 2026 via the Investor Meet Company platform.

 

The presentation is open to all existing and potential shareholders and registration can be completed via the following link: www.investormeetcompany.com/vulcan-two-group-plc/register-investor  

 

Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

 

For further information please contact:

 

Vulcan Two Group plc

Michael Kraftman, Chief Executive Officer

Keith Butcher, Chief Finance Officer

Brendan O’Brien, Chief Operating Officer

www.vulcantwo.com

Email: info@vulcantwo.com

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000
 

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: vulcantwo@almastrategic.com

Tel: +44 (0) 20 3405 0205

 

Notes to Editors

Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise.

For more information, visit www.vulcantwo.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings